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ABSTRACT: The outbreak of a novel coronavirus 2019 was traced back in China in late 
2019, followed by their worldwide transmission as a pandemic. From January to August 
2020, a total of 1,724 papers were published, where 125 were only published in August 
2020, demonstrating the importance and need for current awareness and research to 
overcome this deleterious virus. This paper briefly highlighted the major characteristics 
of the SARS-CoV-2 in detail, including; a brief history of coronavirus, various 
transmission routes, range of mild to severe symptoms, available diagnostic tests, 
treatment options, measures for infection control and prevention, and particular emphasis 
on self-acceptance and upholding to face mask-wearing. The impact of the COVID-19 
pandemic is limitless and has affected all the nation throughout the horizon; the voyage is 
indeed hard but not impossible to overcome. However, it is the responsibility of each and 
every individual to be cautious, know, and understand their role in this difficult situation. 
To conclude, due to the lack of cohesive data, this review has collated the most recent 
literature regarding COVID-19 and provided the reader with clear and simple knowledge 
and instructions on the control and prevention of COVID-19 and hence to protect the 
most vulnerable population. 
INTRODUCTION: On the 11
th
 March 2020, the 
World Health Organization (WHO) has declared 
COVID-19 disease (formerly known as 2019-
nCoV) as a pandemic.  




This article can be accessed online on 
www.ijpsr.com 
DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.12(2).692-13 
It is instigated by a novel coronavirus known as 
Severe Acute Respiratory Syndrome Coronavirus 2 
(SARS-CoV-2) and has infected more than 17 






This virus was first identified in the respiratory 
tract of patients with pneumonia in Wuhan, Hubei 
China, in December 2019 
2
, but it was not until 
January 5
th
 2020, when WHO had been notified of 
the outbreak and resulted in with Wuhan shutdown 
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in January 20
th
 2020. The transformation of the 
disease swiftly changed from an epidemic to 
pandemic worldwide on March 11
th
 by WHO, 
which escalated into national and international 
lockdowns. Since the first case of COVID-19 
reported from Wuhan, all continents across the 
globe followed the same trend and reported cases. 
Epidemiological curves and interactive geographical 
distribution maps have been started updating the 
situation, including old and new cases as well as 
mortality ratios on a daily basis 
3
.  
The aim of this review paper is to compile the 
updated data on the ongoing COVID-19 pandemic 
from the transmission to diagnosis, from symptoms 
and prevention to treatment with a focus upon 
upholding the practice of face masks as a 
significant tool in combating the community spread 
of this pernicious and novel coronavirus. Our goal 
is to facilitate the understanding of the pool of 
information gathered in the open-source literature 
on the lit-COV database 
4
. 
2. History of Coronaviruses Outbreaks in the 
Twenty-first Century: In November 2002, 
Foshan, a city in Guangdong Province of China, 
witnessed the first known case of Severe Acute 
Respiratory Syndrome (SARS). By February 2003, 
cases reached over 300 in mainland China, and 
simultaneously dispersed and spread to other cities 
and countries triggered by infected people’s 
traveling using various means of transportations. 
Taking strong initiative and action by WHO as well 
as a remarkable global effort, the SARS 
coronavirus (SARS-CoV) was identified in early 
April that year. The SARS-CoV epidemic was 
officially controlled by July 2003, and the centers 
of disease control (CDC) and WHO concluding 
more than 8,000 confirmed cases, with more than 
800 deaths in 29 countries 
5
.  
A decade later, in June 2012, a novel coronavirus 
was named ―Middle East respiratory syndrome 
coronavirus‖ (MERS-CoV) due to a man died in 
Saudi Arabia (of acute pneumonia and renal 
failure), and the isolated sputum sample confirmed 
the presence of virus 
6
. Since then, cluster of cases 
of severe respiratory disease had been reported in 
April 2012 in Jordan and had retrospectively been 
identified as MERS-CoV, with addition to three 
other cases reported in the UK in September 2012.  
MERS-CoV continued to emerge and spread to 
countries outside of the Arabian Peninsula as a 
result of traveling (i.e. from infected individuals). 
However, by the end of January 2020, laboratory-
confirmed cases of Middle East respiratory 
syndrome (MERS-CoV) reached to a total of 2519, 
with a case-fatality rate of 34.3% were reported 
globally, amongst which 85% of the cases were 
reported from Saudi Arabia, with a case-fatality 
rate of 37.1% 
7
. A comparison is drawn in Table 1 
between the three identified human coronaviruses. 
TABLE 1: COMPARISON OF EPIDEMIOLOGICAL DATA OF HUMAN CORONAVIRUSES DISEASES AS OF 
JULY 2020 
Information SARS-CoV MERS-CoV SARS-CoV-2 
Zoonotic Intermediate Host Masked Palm Civet, raccoon dog 
8





Geographical origin Goangdong, China Arabian Peninsula Wuhan, China 





















The Coronavirus genus belongs to the family of 
Coronaviridae, order Nidovirales. Members of this 
family are identified to cause respiratory or 
intestinal infections in humans and animals
8
. Bats 
have been confirmed as the origin reservoir of a 
wide variety of coronaviruses, including SARS-
CoV-like and MERS-CoV-like viruses. The 
SARS‐CoV‐2 virus shares genomic sequence 
identity with 88% of two coronaviruses found in 




As the COVID-19 outbreak continues to evolve, 
comparisons have been drawn with Influenza 
disease in order to identify the similarities and 
differences Table 2. Influenza has been anticipated 
as the potential upcoming pandemic by the WHO 
due to the recent 2009 H1N1 pandemic 
10
. As they 
both cause respiratory illness, noticeably, there are 
key differences between the two viruses and the 
way they spread. 
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TABLE 2: THE SIMILARITIES AND DIFFERENCES BETWEEN COVID-19 AND INFLUENZA (FLU) 
PANDEMIC, *HIGHLY DEPENDENT ON THE QUALITY OF THE HEALTHCARE SYSTEM 
11
 
Characteristics Similarities Differences 
Cause Viral infection Different virus; SARS-COV-2 for COVID-19; influenza A 
(H1N1) for Flu 
Symptoms Both have symptoms ranging from 
asymptomatic to severe disease. Common 
symptoms are fever, cough, and shortness 
of breath.  Sore throat, headache, muscle 
ache and fatigue. 
Flu: Mainly common cold symptoms runny and blocked nose, 
symptom developed after 1-4 day from infection. 
COVID-19: Loss of smell and taste appears only in COVID-19 
infection. Typically, symptoms take 5 days after being infected, 
but can appear from 2 days to 14 days after infection. 
People at risk of 
severe infection 
Elderly, underlying chronic illness and 
immunocompromised patients. 
Influenza: Children and Pregnant women. 
Complication Both can result in common complications 
including pneumonia, respiratory failure, 
ARDS and multiple organ failure. 
COVID-19: Multisystem Inflammatory Syndrome in Children 
(MIS-C) is a rare but severe complication, blood clots in veins 
and arteries of lungs and heart. 
Mortality* Both have been reported to lead to eventual 
death with severe infection. 
The estimated mortality rate (3-4%) of COVID-19 is higher than 
0.1% of influenza. 
Transmission Both are contagious respiratory diseases, 
thus means of transmission are similar; 
transmitted by contact, droplets and 
fomites. 
Speed of transmission: shorter incubation period and serial 
interval of influenza spreads it faster than COVID-19. But, a 
person with COVID-19 infection remains contagious for longer 
period than when infected with the Flu and has more super 
spreading events. 
COVID-19: Feco-oral transmission. 
Medical 
Intervention 
Both use antiviral agents in treatment; need 
vaccination. 
Influenza can be treated with antivirals following protocol; 
vaccines are produced annually. 
COVID-19 treatment varies; vaccine is still under development. 
 
2.1. The Structure and Pathogenicity of SARS-
CoV-2: The SARS-CoV-2 viral structure is 
composed of four main proteins in addition to other 
accessory proteins. These main structural proteins 
are: Spike glycoprotein (SG), small envelope 
glycoprotein (SEG), membrane glycoprotein (MG) 
and nucleocapsid protein (NP) Fig 1A and B. The 
SG protein is an outer transmembrane protein 
responsible for binding the viral envelop with host 
cell through attraction with the angiotensin-
converting enzyme 2 (ACE-2); which are expressed 
mostly on type 2 alveolar cells in the lungs; and 
also seen in the colon, kidney, and heart. The NP is 
attached to the vial genome, which is a positive-
sense single-stranded mRNA (+ssmRNA), and thus 
it is important in genome replication cycles and 
regulating host cellular response to viral infections. 
Structural changes in this protein modify the 
affinity of viral binding RNA. The smallest protein 
is the SEG protein, which plays a role in the 
maturation and production of the virus; and the MG 
protein being the largest, as it structures the viral 
membrane and hence shapes the virus. It binds and 
stabilizes the nucleocapsid 
12, 13
. 
Once the SG protein gets attached to the ACE-2 
receptor, the viral membrane fuses with the host 
cell and a certain type II transmembrane serine 
protease (TMPRSS2) present in the cell surface 
cleaves the ACE-2 receptor allowing the virus 
entry into the host cell, causing un-coating and 
subsequently releasing the viral genetic material, 
ready for translation. The rough endoplasmic 
reticulum is where viral transcription and 
translation takes place. First, the non-structural 
proteins (NSPs) are encoded. There are 16 NSPs 
that the viral genome encodes and that play major 
parts in multiple processes within the host cell, 
primarily set in the mechanisms for viral genome 
replication via replicase-transcriptase complex. 
After that, the four structural proteins and 
accessory proteins translation take place in the 
endoplasmic reticulum, where they unite with the 
replicated genome in the endoplasmic reticulum-
golgi intermediate component (ERGIC) to form 
small wallet vesicles ready for expert outside the 
cell through exocytosis 
14
. 
NSPs protect the virus from the host immune 
response before entering the cell and when it has 
entered the host cell. Once they enter the host cells, 
the body’s immune response to SARS-CoV-2 and 
SARS-CoV is similar to being mediated by 
cytokines. An early case report of 99 patients in 
Wuhan has revealed an increase in the total number 
of neutrophils, interluekin-6 (IL-6) serum and c-
reactive protein, and decrease of total lymphocytes 
15
. Others found an increased expression of pro-
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inflammatory cytokines and chemokines; Interferon 
gamma-induced protein-10 (IP-10), Monocyte 
Chemoattractant Protein-1 (MCP-1), Macrophage 
Inflammatory Protein-1 Alpha (MIP-1A), and 
tumor necrosis factor-alpha (TNFa). The antibodies 
produced are generally IgM and IgG, this type of 
infection produces a specific IgM that can only last 
up to 12 weeks, but IgG lasts for a longer period of 
time. In addition to the formation of antibodies, 
exposure to this virus causes the formation of CD4 
T cells and CD8 memory that can last for a much 
longer time i.e., four years. This feature clarifies 
and directs researchers into developing vaccines 




FIG. 1: REPRESENTING (A) SCHEMATIC DIAGRAM OF SARS-CoV-2, AND (B) SARS-CoV-2 UNDER 
ELECTRONIC MICROSCOPE (FDA) 
17 
3. Transmission Routes of COVID-19: 
3.1. Modes of Transmission of COVID-19: The 
novel strain severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) is responsible for the 
new emerging coronavirus disease 19 (COVID-19), 
the disease is extremely infectious and trans-
missible; however, the major causes of its spread 
are still under investigation 
18
. 
Coronaviruses belong to the Coronaviridae family 
and are classified into four genera: alpha (α), beta 
(β), gamma (γ), and delta (δ) coronavirus. The first 
two types ―α and β coronaviruses,‖ are known to 
infect humans (Human Coronavirus, H-CoV), such 
as severe acute respiratory syndrome coronavirus 
(SARS-CoV; β coronavirus) 
19
. Additionally, some 
other coronaviruses have been reported to infect 
wildlife, pets, or livestock, for example, in the case 
of bat coronaviruses (Bat-CoV) Fig. 2. H-CoV 
infects the epithelial cells of the respiratory tract, 
while animal coronaviruses typically infect the 
epithelial cells of the digestive tract. SARS-CoV, 
for example, infects the human lung’s epithelial 
cells by binding to the angiotensin-converting 





FIG. 2: THE KEY RESERVOIRS AND MODE OF TRANSMISSION OF CORONAVIRUSES 
A B 
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Genomic research has shown that SARS-CoV-2 
(COVID-19), which emerged in Wuhan, China, 
and spread all over the world, is phylogenetically 
linked to severe acute respiratory syndrome-like 
(SARS-like) bat viruses; thus, bats could be the 
primary host (reservoir) 
15
. The intermediate host 
and transmission to humans are not yet clear, but 




Infectious agents can spread through various 
pathways from their natural reservoir to a 
susceptible host 
22
. Typically, Infections of the 
respiratory system are transmitted mainly through 
droplets of different sizes. Droplet particles with a 
diameter of 5-10 μm are known as respiratory 
droplets and are responsible for the direct 
transmission (i.e. inhalation of droplets via normal 
tidal breathing). Whereas, smaller droplets/particles 
with less than 5 μm are called droplet nuclei or 
aerosols and are responsible for the airborne 
transmission 
23
. According to the current evidence, 
a number of case studies have provided a 
classification for SARS-CoV-2 mode of transmission, 
including; human-human transmission (primarily 
via respiratory droplets and contact routes), 
airborne transmission as well as environmental 
contamination associated with the fomite and fecal-
oral routes of transmission 
23-25
. Nosocomial 
transmission of SARS-CoV-2 in healthcare 
facilities has also been reported in China, affecting 




3.2. Droplet and Contact Transmission: Based 
on the available evidence to date in literature, it is 
clear that the transmission of SARS-CoV-2 occurs 
in humans primarily when infectious droplets are 
expelled by an infected person (symptomatic or 
not) via sneezing, coughing, exhaling or even 
talking to others 
23-28
. This poses a risk of exposure 
beyond 1 to 2 m distance from an infected 
individual; therefore, the WHO suggested a 1 meter 
(3 feet) of physical distancing 
23
.  
People are most contagious when they show 
symptoms (even mild or non-specific symptoms) or 
they can become contagious for up to two days 
before symptoms occur (pre-symptomatic trans-
mission). In mild cases, they remain infectious for 
an estimated seven to twelve days, whereas in 
severe cases, this can take up to an average of two 
weeks 
29
. It should also be noted that there is 
currently no evidence of SARS-CoV-2 vertical 
intrauterine transmission from infected pregnant 
mothers to their foetuses, while infected mothers 




Transmission may also occur by fomites in the 
immediate vicinity around the infected person. 
Although touching infected surfaces or objects is 
not known to be the primary means of spread of the 
virus, however, the amount of viable active virus 
can be observed for some time Fig. 3. In copper, 
for example, the virus can remain viable for up to 
four hours, in cardboard, for up to one day, and in 
plastics (polypropylene) for up to three days; over a 
particular time, they can no longer cause infection 
or not active/alive 
31
. Therefore, SARS-CoV-2 can 
be transmitted by direct contact with infected 
individuals and by indirect contact with surfaces in 





FIG. 3: A. VARIOUS MODES OF SARS-CoV-2 VIRUS TRANSMISSION FROM PERSON TO PERSON OR VIA 
INCIDENCE OF DIRECT OR INDIRECT CONTACT AND AIRBORNE TRANSMISSION, B. DISTANCE 
HAZARDS OF SARS-CoV-2 VIRUS TRANSMISSION. IN ONE-METER DISTANCE DROPLETS AND AEROSOLS 
MAY BE TRANSMITTED FROM UNMASKED INFECTED PERSON AND INHALED BY A SUSCEPTIBLE HOST 
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3.3. Airborne Transmission: Airborne trans-
mission Fig. 3A occurs through aerosolized small 
droplets and droplet nuclei, which can remain 
suspended and float longer in the air and penetrate 
deeper into the lungs 
32
. The viral transmission was 
found to be a source of the disease because of the 
repeated contacts of infected fomites. As a result, 
several researchers have paid attention specifically 




Upon the earliest occurrence of SARS-CoV-2, the 
WHO stated that an analysis of 75,465 SARS-CoV-
2 cases in China did not indicate airborne 
transmission 
23
. However, experimental findings 
indicate that SARS-CoV-2 may survive for up to 
three hours in the air Fig. 3B, leading to possible 
aerosolized transmission 
31
. Several outbreaks have 
also been reported in crowded and poorly 
ventilated indoor settings, where infected 
individuals stayed for a longer time, such as 
restaurants, coffee shops, takeaways and hotels. 
Aerosols transmission at such sites cannot be 
excluded from the spread of SARS-CoV-2 
33
. 
Among other modes of the virus transmissions, 
there was evidence that the SARS-CoV-2 virus was 
transmitted by faecal contamination caused by an 
infected person 
34
. In the early hours of the 
outbreak of SARS-CoV-2, the WHO confirmed 
that no supporting evidence existed on the faecal-
oral transmission of the virus 
23
. However, recent 
work in China has analysed 1,070 specimens 
collected from 205 infected patients in 3 hospitals 
and identified approximately 29% of positive 
SARS-CoV-2 cases with faecal transmissions. 
Researchers also identified and reported that virus 
remain alive in faeces, suggesting a potential route 
of SARS-CoV-2 transmission via the faecal route 
35
. 
4. Symptoms/Patient Presentations of COVID-
19: Symptoms of COVID-19 infection can be 
divided into typical and atypical symptoms, it 
mainly affects the respiratory system and 
simultaneously affects other systems by changing 
their normal functions. Hence, demonstrating the 
genesis and origination of different symptoms. 
Typical symptoms are the most common symptoms 
featuring the disease; however, it does not mean 
that every patient should experience these 
symptoms to be diagnosed as infected. Moreover, it 
was also identified that some patients tested 
positive for COVID-19 without experiencing any 
symptoms 
36
. It is a complicated scenario but there 
are many factors that could play major roles in 
experiencing such different symptoms or not, 
including patient’s immunity and age. Fever, 
headache and fatigue are the most common 
symptoms of COVID-19 infection, additionally, 
COVID-19 also affects the upper and lower 
respiratory tract causing sore throat, sneezing, dry 
cough, breathlessness but in some cases, the 
production of sputum, rhinorrhoea, dyspnoea with 
hypoxaemia, and haemoptysis Fig. 4 
37
. The 
finding of chest CT scan (computerized 
tomography scan) revealed the presence of grand-
glass opacities and pneumonia, leading to acute 
respiratory distress syndrome 
38
.   
A retrospective study enrolling 262 confirmed 
COVID-19 infected patients aimed to determine the 
clinical and epidemiological characteristics of 
COVID-19 in Beijing. The characteristics between 
severe, mild, non-pneumonia and asymptomatic 
cases reported were 17.6%, 73.3%, 4.2% and 5%, 
respectively. 
 
FIG. 4: REPRESENTING THE MOST COMMON 
SYMPTOMS OF COVID-19 INFECTION IN BEIJING 
Cardiovascular impairment is one of the 
significant multiple organ dysfunction syndrome 
(MODS) associated with COVID-19 infection. This 
can happen due to cytokine storm via direct viral 
infection or exacerbation of already existed 
cardiovascular disease 
39
. A biopsy sample taken 
from heart tissue of the COVID-19 patient showed 
the presence of few interstitial mononuclear inflam-
matory infiltrates 
40
. Similarly, in a series of cases 
involving 138 patients with COVID-19, 10 patients 
(7.2%) have experienced acute cardiac injury (i.e., 
increase serum levels of cardiac biomarkers) 
26
.  
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Coagulation dysfunction could be life-threatening 
in patients with severe COVID-19, as the infection 
is accompanied by disseminated intravascular 
coagulation (DIC), and high risk is involved 
especially if the patients are immobilized 
41
. 
Statistical data regarding coagulation results were 
collected from 183 confirmed COVID-19 patients 
and retrospectively analyzed. It was found that 
71.4% of non‐survivors and 0.6% of survivors have 
experienced DIC during their stay in hospitals 
42
. 
Anosmia (loss of the sense of smell) and ageusia 
(loss of sense of taste) are the other typical 
symptoms of COVID-19 infection. The first 
European case series conducted at the university 
hospital of Sassari to test the olfactory and 
gustatory function of 72 confirmed COVID-19 
patients (27 males, 45 females; mean age 49.2 years 
old), revealed that 53 patients (73.6%) reported 
experiencing chemosensory dysfunctions during 
the infection period 
43
. Anosmia has also been 
reported by epidemiologists and doctors in more 
than 30% of the infected patients in Germany, Italy, 
Switzerland, and South Korea 
44
. 
As regards the occurrence of gastrointestinal 
symptoms (GI), a total of 25,210 patients were 
reviewed from different studies on COVID-19 and 
GI symptoms. The incidence of all GI symptoms 
was 18.6%.  Anorexia, diarrhea, nausea, vomiting 
and abdominal pain were experienced in 26.1%, 
13.5%, 7.5%, 6% and 5.7% patients respectively. 
Pediatric patients have experienced abdominal 
pain, nausea, and vomiting more than adults, 
whereas adults experienced having diarrhea as a 
common factor. It was observed that patients with 
severe disease were experiencing GI symptoms 
more significantly when compared to patients with 
non-severe disease (pooled prevalence is 24.41% 
versus 16.31%, respectively). Intensive care unit 
(ICU) admissions were significantly greater in 
patients with all GI symptoms (9.81%) compared to 
those without GI symptoms (6.70%) 
45
. Another 
study was conducted on 74 confirmed COVID-19 
patients admitted to hospital at Zhejiang province 
with at least one GI symptom (i.e., either nausea, 
vomiting, or diarrhea). Amongst them, 29 
(39.19%), 23 (31.08%), 8 (10.81%), and 16 
(21.62%) patients had significantly higher rates of 
fever (>38.5
o




Neurological symptoms (e.g., cerebral hemorrhage 
and cerebral infarction) are another atypical 
presentation of COVID-19 infection, where the 
patient may not experience any fever or respiratory 
symptoms, hence, may be unaware of his/her 
illness/infection. In a study of 214 patients 
confirmed with COVID-19, 40 patients (18.7%) 
have experienced severe neurological symptoms, 
which require admission to the ICU. Other neuro-
logical symptoms like impaired consciousness, 
headache, dizziness, and acute cerebral disease 
were reported in 78 patients (36.4%) 
47
. Another 
atypical presentation of COVID-19 infection is 
dermato-logical symptoms shown with oral mucosa 
lesions, urticarial lesions, vesicular eruptions, and 
many other types of dermatological manifestations. 
The incidence of these symptoms in COVID-19 
confirmed patients were reported in many studies 
and ranged between 0.2-29%. Studies from China 
and Italy reported dermatological symptoms in 




In recent case reports, some peculiar and 
uncommon symptoms exhibited by patients 
infected with COVID-19 including delirium with 





, neuromuscular manifestation 





, acute pancreatitis with no history of 
past medical illness 
54
, bilateral conjunctivitis 
55
, 
and guillain barre syndrome 
56
. 
5. Diagnostic testing of COVID-19: Diagnostic 
testing can be conducted in order to reveal if the 
suspected individuals are positive (have infections) 
or negative (infection free) for SARS-CoV-2, if 
positive, the proper measurements can be adopted 
to treat as well as to curb the spread of disease
57
. 
Diagnostic testing of the SARS-CoV-2 infection is 
based on one of the following methods Fig. 5: 
 Antigen test (detection of viral protein on 
the surface of the virus or the viral RNA 
and the molecular material) 
58
. 
 Antibody test (identification of antibodies 
in human blood produced during the 
immune response to the virus) 
59
. 
 Imaging (recognition of infection via chest 
x-ray and CT scan) 
60
.  
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5.1. Antigen Test: Antigen test Table 3 is 
characterized as the fast response to get to know 
the presence or absence of virus; however, it can 
sometimes display negative results; therefore, a 
molecular test can be done to confirm the results 
for the SARS-CoV-2 
59
. A molecular test is carried 
out in order to detect the unique viral RNA 
sequence i.e., nucleic acid amplification test (NAAT), 
post-amplification of the nucleic acid, specific 
sequencing can be confirmed such as real-time 
reverse transcription-polymerase chain reaction 
(rRT-PCR) through the extraction of the RNA 
61
. 
The antigen testing can be conducted via two 
common techniques; nasopharyngeal swab or 
oropharyngeal swab. Nasopharyngeal swab is more 
common, and it can be done by the patient; 
however, sample collection should be done 
accurately (i.e. right place, swabbing time, and 
swabbing technique). After collecting the specimen, it 
should be carried to the laboratory at a temperature 
below 4°C without interacting with the external 
environment. In China, an oropharyngeal swab was 
performed more than the nasopharyngeal swab 
during the SARS-CoV-2 outbreak, and it showed 
that the oropharyngeal swab (32% was positive) 
was less sensitive in detecting the virus antigen 
compared to the nasopharyngeal swab (63% was 
positive). This sensitivity might be attributed to the 
relocation of the virus from the upper respiratory 
tract to the lower respiratory tract, where it changes 
its location of replication and hence gives negative 
results. However, if the swab has been taken via 
nasopharynx, repeated testing from the lower 
respiratory tract is required in suspected patients 
with SARS-CoV-2 symptoms 
62
.  
In early 2020, CDC developed its first laboratory 





FIG. 5: VARIOUS DIAGNOSTIC TEST THAT CAN BE EMPLOYED TO IDENTIFY THE PRESENCE OR 
ABSENCE OF COVID-19 IN HUMAN INDIVIDUALS 
5.2. Antibody Test: Antibody is a protein 
produced by the immune system in response to the 
antigen to fight infection and prevent the future 
proliferation of viral infection by the same antigen. 
Antibodies might not be used in the diagnosis and 
screening because they cannot detect antigens. 
There are serological (blood) tests and antibody 
tests for SARS-COV-2, which are very simple; 
however, they still require some improvements. 
The antibody test is used to detect immunity for 
exposed populations, transmission, and progression 
of the disease 
64
.  
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5.2.1. Antibody Test Types: 
 Enzyme Immunosorbent assay (EIA) is used 
for the detection of antibodies against SARS-
CoV-2 protein.  
 Enzyme-linked immunosorbent assay 
(ELISA) is used for the detection of previous 
exposure to the virus; where IGM can be 
detected within days, IGG can be detected 
within weeks (and stays after exposure and 
have a protective role). This test is deemed to 
be simple and can be employed for multiple 
samples from one patient, however, one of the 
limitations of this test is that the results may 
defer according to the time of sampling in 
addition to the test reliability in determining 
both false positives and false negatives 
65, 66
. 
 Lateral Flow Immunoassay (LFI) consists of 
portable diagnostic strips to detect antigens 
and antibodies. These tests are rapid, 
sensitive, and specific. However, the main 
limitation is that it is very challenging when it 




 Serum Virus Neutralisation (SVN) determines 
the ability of antibodies to neutralize the 
antigens and reduce the infection. This test is 
considered to be the most consistent and 
promising for the assessment of antibody 
presence. The main disadvantage of the test is 
that the access to live SARS-CoV-2 samples 
are under strict regulations, limiting its 
availability to the laboratories due to the strict 




5.3. Imaging: At present, COVID-19 diagnosis has 
been achieved through reverse transcriptase-
polymerase chain reaction (rRT-PCR) assays via 
the identification of viral RNA. However, if rRT-
PCR is not feasible for diagnostic testing, chest 
imaging is thought to be an alternative source to 
determine Covid-19 positive patients alongside 
with the symptoms present in infected individuals. 
Imaging is considered as a complementary test in 
addition to the various laboratory and clinical 
parameters in patients already diagnosed with 
COVID-19 
70
. Chest imagining is beneficial and 
required in emergency conditions, when patients 
have one of the COVID-19 complications 
(pneumonia, pulmonary thrombosis or 
thromboembolism) or live with other high-risk 
patients (e.g. immunocompromised, persons aged 
over 60 years). 
The majority of COVID-19 infected individuals do 
not usually develop pneumonia
71
; nevertheless, 
when people are dropped to hospitals with severe 
respiratory symptoms, chest radiography is used to 
determine those with COVID-19 pneumonia. Some 
hospitals employ portable chest radiography as a 
technique to reduce the patient transfer from one 
area to another and eventually reducing the need 
for personal protective equipment (PPE). However, 
portable chest radiography is not sensitive in early 




TABLE 3: SHOWING THE SAMPLING PROCEDURE, ANALYSIS TIME, REQUIREMENTS AND LIMITATION 
ASSOCIATED WITH VARIOUS TESTS (i.e. MOLECULAR, ANTIGEN, AND ANTIBODY TESTS) FOR SARS-CoV-2 
59
 
Tests Molecular Test Antigen Test Antibody Test 
Other names Diagnostic test, viral test, RT-PCR 
test, nucleic acid amplification test 
(NAAT), molecular test 
Rapid diagnostic test 
 
Serological test, serology test 
Sampling 
procedure 
Naso or Oropharyngeal swab (most 
tests) Saliva (a few tests) 
Naso or Oropharyngeal swab blood draw or Fingerstick 
Results time Same-day or up to 7 days One hour or less Same-day or 1-3 days 
Other tests 
required 
None Test results are accurate upon 
positive obtaining results, but 
negative results are confirmed with 
a molecular test 
Occasionally a second antibody 




Diagnoses active COVID-19 
infection 
Diagnoses active COVID-19 
infection 
Confirms the previous 
infection with COVID-19 
Test 
limitations 
Does not show a previous infection Definitively rule out active COVID-
19 infection 
Diagnose active COVID-19 
infection at the time of the test 
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In a study conducted by Guan et al., (2020) 
72 
and 
Wong et al., (2020) 
73
 where they demonstrated 
that portable chest radiography has 59% sensitivity 
towards initial detection of abnormalities related to 
COVID-19. A quantitative meta-analysis study in 
Australia and China established that COVID-19 
pneumonia affected the bilateral side of the lungs 
upon chest radiographs (72.9%) and have ground-
glass opacity in 68.5% of cases 
74
. Chest CT have a 
role in the assessment of patients presenting with 
severe respiratory symptoms. Chest CT has a 
comparatively high sensitivity but moderately low 
specificity. Though, the absence of radiological 
signs of pneumonia cannot be ruled out in the 
presence of a viral infection 
75
. In the early 
detection of infection, chest radiography has lower 
sensitivity but rather is useful in the follow-up 
stage, where it has higher specificity. Chest 
radiography is associated with a lower amount of 




6. Treatment options of COVID-19: Up to date, 
there is no definitive treatment for coronavirus 
2019, but efforts are made to prevent, manage and 
support healthcare in order to provide relief in the 
outbreak of SARS-CoV-2. A wide range of 
medicines have been used for the treatment of 
COVID-19 treatment including; oxygen therapy, 
antiviral drugs, antibacterial drugs, glucocorticoids, 
and traditional Chinese medicine; however, till 
now, no specific medications have been approved 
for the COVID-19 treatment 
77
. 
6.1. Treatment Strategies: 
6.1.1. Oxygen Therapy: Oxygen therapy (O2) is 
essential for severe cases of COVID-19 Fig. 6. The 
administration of partially ionized oxygen 
considers as another type of oxidation therapy, is 
not a frequently used method; however, its success 
was proven. O2 causes direct inactivation of the 
virus through oxidation of the membrane glycol-
proteins. The use of this method needs a special 
medical device and require hospitalization. 
Moreover, the effective time of oxygen inhalation 
for virus inactivation has not been estimated yet 
78, 
79
. Clinical studies have proven that the use of O2-
therapy by high-flow nasal cannula (HFNC) in 
patients with severe hypoxemic acute respiratory 
failure (hARF) caused by SARS-CoV-2 infection is 
a safe and effective treatment for less severe 
patients with SARS-CoV-2 hARF; however, the 





FIG. 6: SCHEMATIC DIAGRAM SHOWING THE TREATMENT ALGORITHM 
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6.1.2. Antiviral Drug: Following the outbreak of 
new coronavirus-2019 (SARS-CoV-2) that was 
started in Wuhan on December 2019 and the 
absence of vaccine had determined the search for 
antiviral drugs, who would have the to inhibit the 
viral replication and block the infection 
82-84
. 
Studies demonstrated that the antiviral drug has 
been proven to block SARS-CoV and MERS-CoV 
85
. The same antivirals were used for the therapy of 
COVID-19, Remdesivir was found to be effective 
in hospitalized patient with additional requirement 
of supplemental oxygen when O2 saturation was < 
94%. However, no benefit was observed in mild to 
moderate COVID-19, when patients were treated 
with Remdesivir (i.e., intravenous administration 
for 10 days; 200 mg on the first day, and 100 mg 
daily over the next 9 days) 
86
. Even Lopinavir and 
its booster Ritonavir did not show any benefit in 
treating COVID-19 infection 
87
. Nonetheless, when 
Remdesivir was combined with ribavirin or 
interferon-1β, it is far more effective and produced 
less side effects. Interferon-β1b was not included in 
the triple therapy if onset of symptoms exceeded 
seven days due to concern of its potential to cause 
inflammatory response, delayed administration 
may worsen the patient’s condition and intensify 
the cytokine storm 
86
. The use of Umifenovir 
combined with Lopinavir/Ritonavir was also found 
to be more efficacious than Lopinavir/Ritonavir 
alone 
88
. Favipiravir is another antiviral drug that 
was found to be more efficacious when used in 
combination with Lopinavir/Ritonavir than using 
Lopinavir/ Ritonavir alone 
85, 89
. 
6.1.3. Immunotherapy: Plasma therapy was used 
widely in the treatment and prevention of infectious 
disease due to the similarity of viral and clinical 
characteristics among SARS-CoV, MERS-CoV, 
and SARS-CoV-2; as plasma therapy was 
considered as an effective alternative strategy in the 
treatment of COVID-19. Patients who have recovered 
from COVID-19 possessing high neutralizing 
antibody titers considered as a potential source of 
convalescent plasma. Convalescent plasma therapy 
may cause a blockage of viral infection and will 
held in viral clearance through the transfer of sera 
containing anti-SARS-CoV-2 antibodies 
90
. Studies 
have demonstrated a response within seven days of 
treatment with no adverse effects of convalescent 
plasma therapy in few severe COVID-19 patients 
in China. However, further studies are needed to 
determine their optimum dose 
91
. The risks 
associated with the convalescent plasma therapy 
may include transfusion-associated circulatory 
overload, transfusion-related acute lung injury and 
allergic reactions that may cause mortality 
92
. 
6.1.4. Bioactive Compounds: These compounds 
showed antiviral activities and effectiveness against 
SARS-CoV, MERS-CoV, and SARS-CoV-2. The 
ginsenoside-Rb1 from Panax ginseng and aescin 
from Aesculus hippocastanum possessing anti-
SARS-CoV properties. Also, pharmacologically 
active compounds like reserpine, leptodactylone 
and lycorine have shown to be effective against 
SARS-CoV. The lipophilic compound like resveratrol 
and dihydrotanshinone have an inhibition effect of 
MERS-CoV infection. Emodin extracted from 
Rheum palmatum blocks the interaction of SARS-
CoV-S protein with ACE-2 receptor. Studies of 
molecular docking have indicated that stilbene-
based natural compounds and a potent Mpro 
inhibitor, oolonghomobisflavan-A from tea plant, 
are promising candidates against SARS-CoV-2 93-95. 
6.1.5. Antibodies Therapy: Coronavirus patients 
with severe lung damage and elevated interleukin 6 
levels used an immunosuppressive drug, which is 
mainly employed in the treatment of rheumatoid 
arthritis-like Tocilizumab expected to have a 
positive effect. Meplazumab demonstrated an 
important role in the interaction between spike 
protein of SARS-CoV-2 and lung epithelial cells; 
however, further studies would be required in order 
to prove their efficiency 
86, 96
. 
6.1.6. Hydroxychloroquine and Azithromycin: 
Hydroxychloroquine and azithromycin have been 
employed in the treatment of patients infected with 
COVID-19. Though, evidence on the safety and 
efficacy of these treatments are inadequate. Studies 
are demonstrating the possibility of using hydroxyl-
chloroquine as prophylaxis for coronavirus to 
achieve a positive response in the treatment of 
SARS. The pre-treated cells with chloroquine were 
refractory to the virus and revealed an impairment 
of terminal glycosylation of the ACE-2 receptor, 
decreasing viral-receptor affinity and therefore 
reducing the initiation of the infection 
97, 98
. The 
antimalarial drugs chloroquine and hydroxy-
chloroquine have been found to have potential anti-
SARS-CoV-2 activity and showed a good response 
in clinical treatments.  
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Restriction of use of these drugs is associated 
especially with side effects on the heart and eyes 
77
. 
The most common adverse effects associated with 
these drugs are gastrointestinal reactions, such as 
diarrhoea and vomiting 
77
. 
Negative results of rRT-PCR for SARS-CoV-2 
from nasopharyngeal swabs were achieved in 80 
patients with mild infections, 83% on day 7, and 
93% after administration of Hydroxychloroquine 
and azithromycin. It was demonstrated that patient 
characteristics impacted and affected the treatments 
as different responses have been reported in 
different studies, including the combined use of the 
Hydroxychloroquine and azithromycin 99.  
6.1.7. Corticosteroids: Steroids are not considered 
to be recommended in the treatment of viral 
pneumonia or acute respiratory distress syndrome 
(ARDS) as per the WHO recommendations, as 
there is no clinical benefit recorded 
86
. Dexametha-
sone was found to be useful with 6 mg per day for 
up to 10 days for the treatment of COVID-19 in 
patients, and particularly in those patients who are 
mechanically ventilated and require supplemental 
oxygen, whilst, it is not recommended to be used in 
patients who do not require supplemental oxygen 
100
. Dexamethasone is a strong corticosteroid, and 
their longer use is causing an inhibitory effect on 
the cytokine. Also, it prevents the formation of the 
antibodies by inhibiting the T cell and B cell 
leading to an increase in the plasma viral load. 
Dexamethasone demonstrated effectiveness in 
severe COVID-19; however, it is dangerous during 
the recovery period. This is due to antiviral and 
anti-inflammatory effects of corticosteroid and 
their ability to inhibit mast cells. The effect of the 
other corticosteroid like prednisone, methyl-
prednisolone, and hydrocortisone with the dose 
equivalent to 6 mg of dexamethasone is not 
approved therapies 
100-102
. Clinicians must carefully 
monitor COVID-19 patients who are getting 
dexamethasone for adverse effects (e.g. secondary 
infections, hyper-glycaemia, avascular necrosis, 
and psychiatric effects) 
101
. 
6.2. Heat and COVID-19: With the other personal 
hygiene measures, a heat-based method can be used 
to help in overcoming COVID-19 by preventing 
drying of the nasal mucosa, increase mucociliary 
clearance, nasal patency, and provide symptomatic 
relief. The direct application of the heat may inhibit 
the virus at the early stage of infection, the immune 
cells were activated, heat shock proteins (Hsps) 
released, and rhinovirus multiplication showed 
suppression by more than 90%. Reduction in the 
viral load along with physical and psychological 
relief is associated with the inhalation of the steam 
with additional substrates (i.e., essential oils, anti-




At present, there is no clinical protocol for using 
the heat method in the treatment of COVID-19. 
Traditional use of heat has a long history, and 
traditional practices such as alternating hot and 
cold immersions, post-heat relaxation, and use of 
essential oils can inform their development. 
Contra-indications of this method such as unstable 
angina, severe infection, or high fever along with 
factors such as age, weight, fitness, hydration 
status, co-morbidities, and the use of alcohol or 
prescription drugs to be considered in the protocols. 
Using hydrotherapy treatment requires considerations 
in terms of timing, temperature, and humidity, as 
water is 25 times more conductive than air, making 
steam rooms tolerable at temperatures around 50 
°C, while dry saunas are tolerated at temperatures 
above 100 °C. Further advantages of heat-therapy 




7. COVID-19 Infection Control and Prevention: 
Referral to various protocols set by health care 
professionals is a must in order to prevent and 
control the infection protocols Fig. 7. All SARS-
CoV-2 suspected or confirmed cases in an area 
should be immediately isolated from other patients 
in adequately ventilated single rooms or ensure 
there is at least one meter between patients 
106
. 
Healthcare workers also require a high level of 
protection using the appropriate personal protective 
equipment (PPE). A cross-sectional study comprised 
of 420 healthcare workers, who tested negative for 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) in Wuhan, the study showed 
that standard surgical masks are as protective as 
respirator masks for preventing viral respiratory 
infection such as influenza, but it is unidentified if 
this is the case in COVID-19 
107, 108
. Most general 
practice clinics operate remotely through a 
telephone or video consultations 
109
. 
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FIG. 7: PROFESSIONAL RECOMMENDATIONS FOR COVID-19 PREVENTION 
7.1. General Prevention Measures for the 
General Public: People are advised to use an 
alcohol-based hand sanitizer (that contains at least 
70% of alcohol) or alternatively wash hands with 
soap and water for at least 20 seconds, particularly 
after coughing/sneezing. Also, avoid touching the 
mouth, eyes, and nose with dirty hands 
110
. 
Maintaining a distance of one meter was advised 
and avoided handshaking, particularly with those 
exposed to COVID-19 patients or those who 
possess such symptoms (fever, coughing, or 
sneezing).  
 
FIG. 8: COVID-19 GENERAL PREVENTATIVE MEASURES FOR THE GENERAL PUBLIC 
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The recommended distance requirements are 
different in every country (two meters in the USA 
and UK) 
111
. The instruction also includes 
following the proper respiratory hygiene, i.e., use a 
tissue when coughing or sneezing, catch the sneeze 
or cough on the elbow, and then discard the tissue 
in a closed bin. People are advised to seek medical 
advice if any symptoms are developed, 
alternatively self-isolate at home until recovery 
from any mild symptoms. Finally, cleaning all the 
surfaces daily, e.g., light switches, phones, door 
handles, may minimize the transmission of the 
virus from one person to another Fig. 9. 
7.2. Use of Face Masks for COVID-19 
Prevention of Transmission: 
7.2.1. Importance of Face Masks: The use of 
masks was considered unnecessary and to be 
somehow possibly harmful before the SARS-CoV-
2 (COVID-19) crises, which became mandatory in 
many places across the globe. The universal use of 
face masks is extremely useful and needed to probe 
transmittance of COVID-19 from asymptomatic, 
symptomatic or pre-symptomatic carriers. It was 
suggested that face masks play a pivotal role in the 
prevention as well as spread and control of disease 
transmission. These masks also help healthy people 
who have exposure to infection and infected people 
who have more chances to spread the disease. 
Therefore, in order to reduce the diffusion of 
COVID-19, the Centres for Disease Control and 
Prevention (CDCP) in the USA modified the 
recommendations in April 2020 that healthy people 
and healthcare workers should cover their face 
(using masks) when go out in public 
112
, which 
showed a meaningful decrease of COVID-19 
transmission in the community as well reduce peak 
hospitalization and deaths 
113
. A similar approach 
was also adopted by Europe and Asia 
114
. Many 
studies have supported the hypothesis that face-
covering using surgical masks and N95 respirators 
are effective against the transmission of droplets 
containing viral particles generated by the COVID-
19 patients 
115
. However, the current pandemic 
situation of COVID-19 led to the global shortage of 
commercially available mask in early 2020 which 
have directed people to use handmade masks and 
mask alternatives. It was assumed that the use of 
such masks would reduce the likelihood of 
spreading of disease. However, most such masks 
and their designs have not been tested in practice. 
The effectiveness of homemade face covering is 
still debatable in terms of transmission of droplets 
(through nose or mouth via cough, sneeze, breath, 
and talk), whereas surgical masks can prevent them 
in case of large droplets, but airborne particles (in 
sub-micron size) were not determined 
116
. 
7.2.2. Statistics of Face Masks: The database of 
PubMed was searched between the years 1946 and 
2020 for the key term ―face mask‖, where a total of 
5,216 publications (including books and documents, 
clinical trials, meta-analysis, randomized controlled 
trials, reviews, and systematic reviews) were found. 
The number of publications published on face 
masks is significantly higher in 2020 (i.e., 511) 
when compared to any individual year Fig. 9.  
 
FIG. 9: NUMBER OF PUBLICATIONS PUBLISHED BETWEEN 1946 AND 2020, DEMONSTRATING A 
SIGNIFICANT INCREASE IN THE NUMBER OF PUBLICATIONS USING A KEY WORD “FACE MASK” USING 
PubMed ONLINE DATA, AND ESPECIALLY FOR THE YEAR 2020 
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Furthermore, the number of publications released 
from February are also illustrated to show the 
breakdown of the available literature online. This 
further suggested the importance and increased 
awareness of researchers towards the community in 
order to evaluate various types of masks, their use, 
and their importance to protect the community and 
to curb the spread of disease. 
7.2.3. Selection, Effectiveness and Performance 
of Masks: The answer to the question of the best 
effective mask is not exactly straightforward, 
especially when it comes to COVID-19. Some of 
the general qualities and characteristics that the 
best mask may possess are; easy to wear, reusable, 
show no irritation, recyclable, possess low level of 
discomfort and high level of breathability and not 
the least to resist the permeability of droplets 
and/or COVID-19 virus. Droplet permeability is 
the most important quality that masks should hold. 
For droplets permeability, a very simple method is 
spraying spray droplets over the mask and hence 
check the amount of droplet pass through the mask. 
This may identify the difference between N95, 
medical, homemade (one to three-layer masks, 
made from various fabrics i.e. linen, silk, polyester 
and cotton) and alternative masks. It was identified 
that during speaking through alternative masks 
especially using neck fleece disperse large droplets 
into smaller droplets, which further increase the 
number of droplets, making the situation worse 
(than using such masks). Smaller droplets are light 
and stay in the air for a longer time when compared 
to large droplets, which have a higher tendency to 
settle due to their higher density/mass. Similarly, 
bandana or scarf also demonstrated low resistance 
to the droplet penetration 
117
. 
The fabric used for the face mask may have wobbly 
or tighter weave and thicker or thinner thread to 
block/allow the droplets to pass as well as 
breathability Table 4. There should be a balance 
between the permeability of droplets and the 
thickness of fabric for breathing. If there is an 
imbalance, that may lead to the defeat of the 
purpose of the mask, and hence the use of such 
masks would give a false sense of safety. The 
thicker fabric will make it hard to breathe normally, 
and hence the airflow would come through the 
sides, but if the fabric is too loose and droplets can 
easily pass through that (due to less resistance 
offered by fabric). It was found that cloth masks 
(especially with one layer) possess high 
breathability 
118,
 but at the same time, they are more 
permeable to the droplets and therefore 
compromised the barrier interface between healthy 
and infected individuals Table 4. A study using a 
laboratory setting demonstrated that 97% of a 
particle can penetrate through the cloth mask when 
compared to only 44% of particle penetration 
through medical masks 
119
. Another study showed 
that homemade masks, including cotton, silk, 
polystyrene, linen may significantly decrease 
particles and droplets transmission when coughing 
or sneezing, but their efficiency is still lower than 
surgical masks 
120
. Therefore, homemade cloth 
mask with two and three layers are more resistant 
to the transmittance of particles/droplets across the 
mask but still possess good breathability. 
Moreover, another study conducted between the 
use of 3 layers cotton mask and a surgical mask to 
assess the transmission of respiratory droplets. It 
was found that there is no significant difference 
between both types of masks, and a 3-layer cotton 
mask can be used daily in the community 
121
. 
Masks from three-layered cotton shirts showed 
higher breathability than medical masks.  
Surgical masks are more often used in operation in 
order to protect from patient body fluid (oral and 
nasal), sneezing, and coughing. It has been used for 
decades; however, its fitting is loose, allowing a 
potential leakage of aerosol droplets through open 
ends Table 4. High-efficiency particulate air 
(HEPA) masks are considered the best masks due 
to their filter that can collect particles efficiently 
when compared to surgical mask filters as well as 
cloth filters (don’t contain any filter). However, 
these filters are affected by the moisture from 
exhaled air due to the tight-fitting to the face hence 
leading to limit their extended use Table 4. Masks 
can be chosen based on their comfortability even 
using it for a longer period of time. Upon 
comparing between valved and non-valved N95 
masks (HEPA masks), it may be suggested that 
during exhalation, the inward and outward airflow 
is strong through the valve that may affect the 
valve and hence are not more useful than the non-
valved N95 masks. Overall, it was recognized that 
the face mask is the requirement of the day in the 
current pandemic. The use of N95 or other HEPA 
filter masks is better in terms of safety and 
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resistance to external environments. Homemade 
masks can be a good alternative tool to render 
disease spreadability in the absence of other masks 
Table 4. 
7.3. Screening and Quarantine: Screening the 
people coming from a high-risk of infection areas 
using questionnaires related to their travel history, 
any symptoms of infection temperature 
measurement. It has been reported that the 
Symptom-based screening process was deemed to 
be ineffective in the detection of SARS-CoV-2 
infection, who later tested positive when samples 
were taken using a throat swab 
122
. Obligatory 
quarantine was employed to isolate groups of 
people evacuated by planes, people coming back to 
their home country before borders closure 
123
, 
Public Health England emphasises on the need to 
self-isolate for 14 days upon arrival to the country. 
7.4. Social Distancing: Most countries around the 
world have applied compulsory social distancing 
measures in order to delay or minimize the 
transmission, i.e., curfews, staying at home, local 
cities lockdown, universities, and school closures, 
working from home, and banning travel
124
. 
Simulation models run by Singapore investigators 
demonstrated that social distancing measures 




7.5. Shielding Susceptible People: Shielding is 
used to protect susceptible people with a pre-
existing health condition. Shielding comprises 
diminishing all possible contact between susceptible 
people and healthy people to protect them from 
contracting the virus. Extremely susceptible groups 
comprise of organ transplant patients, cancer 
patients, asthmatic or any other related respiratory 
conditions, people on immunosuppressive 
therapies, pregnant women with heart disease 
127
. 
7.3. Prophylaxis from COVID-19: 
7.3.1. Role of Vitamin C, Zinc and Vitamin D in 
the Prophylaxis for COVID-19: Vitamin C has an 
antioxidant role through the savaging of reactive 
oxygen species; several researches recommended 
that vitamin C supplementation can have a positive 
effect on boosting the immune system. 
Furthermore, human trials demonstrated that 
vitamin C may reduce the vulnerability to viral 
respiratory infections and pneumonia 
128
. Large 
doses of vitamin C have been shown to decrease 
the duration and severity of the symptoms caused 
by rhinovirus 
129
. A study conducted by Carr 
(2019) on severely ill hospitalized patients 
demonstrated mixed results on the duration of 
mechanical ventilation, length of stay in the 
intensive care unit, and mortality 
130
. Nevertheless, 
intravenous high doses of vitamin C were mostly 
safe. The influence of vitamin C in the treatment of 
patients with COVID-19 is still unclear 
131, 132
. 
Zinc demonstrated its role in boosting the immune 
system through white blood cell and antibody 
production. Zinc deficiency causes the elevation of 
pro-inflammatory cytokine concentrations (TNF 
alpha, Interleukins (IL-1 and IL-6) and reduces the 
synthesis of antibodies. Supplementation with zinc 
has proved to increase the ability for poly-
morphonuclear cell production and infection-
fighting 
128
. Elevated intracellular concentrations of 
zinc showed an inhibition effect on the viral RNA 
polymerase activity and thus its replication inside 
the cells 
133
. Although zinc has shown an amazing 
effect on boosting the immune system, its effect in 
offering prophylaxis against COVID-19 is still 
unclear. 
Vitamin D originates from dairy products and oily 
fish, and its biologically activated form 25-
hydroxyvitamin D on the skin under sun effect on 
7-dehydrocholesterol. An in vitro, vitamin D causes 
secretion of type 1 interferon, antiproliferative 
effects on T cells, inhibition of antigen-presenting 
cells, modulating expression, and inhibition of 
proinflammatory cytokine expression (TNF alpha 
and IL-6) 
134
. During the winter season 40% of the 
USA population are experiencing vitamin D 
deficiency, older age, darker skin, and 
corticosteroid use are at higher risk of developing 
vitamin D deficiency which has been associated 
with a higher occurrence of acute respiratory 
infections 
135
. Several randomized trials have 
shown the implication of vitamin D use in the 
prevention of acute respiratory infection, where a 
dose of < 25 nmol/L demonstrated a protective 
effect against infection 
136
.  
7.3.2. COVID-19 and Vaccines: At the present 
time, there are no definitive vaccines available; 
they are rather in the development and clinical trial 
stage. It might take up to 18 months to develop a 
safe and effective vaccine. 
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However, mRNA and DNA platform vaccines, 
adenovirus vector vaccines, and inactivated virus 
vaccines are currently approved for clinical testing 
on humans 
137
. Former trials of coronavirus 
vaccines demonstrated antibody-dependent 
enhancement (ADE) and cellular immune response 
as possible safety matters 
138
. 
TABLE 4: REPRESENTING IMPORTANT FACTORS OF VARIOUS FACE MASKS DEMONSTRATING THEIR 
SUITABILITY AND PERFORMANCE IN THE CURRENT SARS-CoV-2 PANDEMIC 
Face mask Characteristics Manufacturing 
and Layers 
Advantages Disadvantages Reusable 
Cloth mask Cover face and 
mask and fitting 







These masks are circa 15% less effective 
than surgical masks. 
Cloth masks are 5 times more effective 
than wearing no mask. 
Not suitable for children 
≤2 years. 






Cotton mask May be loose 
fitting. 
May be tight/close 
fitting covering 







To avoid direct face touching. 
Work as a barrier like covering during 
coughing and sneezing. 
Filtration efficiency with 3 layers is 86%. 
Not suitable for children 
≤2 years. 





washing. 120, 121 
Surgical 
mask 
Loose fitting over 





Breathable but breathing difficulty is 30%. 
Available in different sizes. 
Blocking respiratory droplets. 
Fluid barrier. 
Fluid resistant. 
Suitable for children ≥3 
years. 
More waste as not 
reusable. 
Discomfort level 41%. 
Designed to be 






Tight fitting over 
nose and mouth. 
Manually 
attaching filter 
over AFM via 
adhesive taps or 
harness. 
 










Occlusion test can be performed to check 
the airtight fitting. 
Available in different sizes. 
For better comfort, has air inflation 
port/valve for customized fit. 
Washable. 
Filtration efficiency is 99.99% compared 
to N95 (95%). 







Filter can be 
changed based 
after 24 h 142 
KF80 Mask 
 
Tight fitting over 
nose and mouth 
and creating seal 




Filter efficiency is 80% (large and small 
particles). 
Decrease exposure to fine dust particles. 
Not fluid resistant. 
Not usable in low 
oxygen air i.e. <18%. 







before use. 120 
N95 Tight fitting over 
nose and mouth 
and creating seal 





Filter efficiency is 95% (large to small 
aerosol droplets). 
Fluid resistant. 
Not usable in low 
oxygen air i.e. <18%. 
Breathing difficulty is 









before use. 120, 
141 
 
CONCLUSION: COVID-19 has been declared a 
public health emergency of global concern by the 
WHO. At present, there are many other infections 
(seasonal and regular); however, there are concerning 
aspects to this emerging infection, have greatly 
affected the individual globally. Researchers have 
made improvements in the characterization of the 
coronavirus and working on formulations and 
vaccines in order to overcome this viral infection. 
In this paper, we have summarised the available 
literature for COVID-19 as follows; the history of 
developing pneumonia, the cause and virulence of 
COVID-19 (caused by SARS-CoV-2) when 
compared to SARS-CoV and MERS-CoV, the role 
of ACE-2 receptor, and the presence of different 
mild to severe symptoms contain by patients. 
Moreover, the availability of antigen and antibody 
testing with imaging techniques were discussed to 
analyse the viral infection in more detail. A number 
of various treatment options were discussed 
(antiviral, antibiotics, steroidal, immunotherapy to 
oxygen therapy) to highlight the best available 
treatment option.  
Another major emphasis was conducted to focus 
the importance of infection control and prevention. 
Thus, the use medical masks (of various designs 
and shapes) were identified as the key requirement 
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of the day. Globally, face masks have a minimal 
impact on socio-economic life but potentially have 
a great role in decreasing the spread of this life-
threatening disease. Moreover, in the current 
scenario, global and national recommendations and 
guidelines are required with infection prevention 
and control measures to provide consistent and 
clear criteria for the use of facial protection as well 
as available treatment. 
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